Insider Trading June 24, 2026 09:36 AM

Aflac Director Joseph Moskowitz Offloads $1.44 Million in Shares Amid Near 52-Week High

Insider activity reveals partial profit-taking as the insurer navigates mixed quarterly results and recent corporate governance updates.

By Sofia Navarro
Share
Twitter Reddit Facebook LinkedIn
AFL

Joseph L. Moskowitz, a director at AFLAC INC (NYSE:AFL), executed a divestiture of company equity totaling approximately $1.44 million on June 22, 2026. The transactions occurred as AFLAC stock traded near its 52-week peak of $119.81, with the share price recorded at $118.21. This insider activity coincides with the company's recent financial reporting period and corporate governance developments, including a first-quarter 2026 earnings release that showed revenue beats offsetting an earnings per share miss.

Aflac Director Joseph Moskowitz Offloads $1.44 Million in Shares Amid Near 52-Week High
AFL
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Joseph Moskowitz sold 12,370 shares of AFLAC stock at prices between $116.54 and $116.58, realizing a total value of approximately $1.44 million.
  • The sale occurred as AFLAC shares traded near their 52-week high of $119.81, with current pricing at $118.21.
  • Aflac reported mixed first-quarter 2026 results, with revenue of $4.35 billion beating forecasts despite an adjusted EPS miss of $1.75 versus the expected $1.80.

Joseph L. Moskowitz, serving as a director at AFLAC INC (NYSE:AFL), executed a divestiture of company equity totaling approximately $1.44 million on June 22, 2026. According to a recent SEC Form 4 filing, the director disposed of 12,370 shares of common stock. These transactions were executed across multiple trades at prices ranging from $116.54 to $116.58 per share. The weighted average sale price for a portion of these shares was recorded at $116.543.

The timing of this sale is notable given the current market position of AFLAC shares. The stock was trading near its 52-week high of $119.81 at the time of the transaction, with the current price listed at $118.21. Market analysis suggests the stock may be slightly overvalued relative to its calculated Fair Value.

Before executing the sale, Moskowitz had acquired 20,303 shares of AFLAC common stock by exercising director stock options. The exercise price for these options was $44.59 per share, representing a total value of $905,310. Following these transactions, Moskowitz directly holds 33,310 shares of AFLAC common stock.

The insurance giant, valued at $60.5 billion, has delivered a 16% return over the past year. This performance comes amid a period of mixed financial results for the company. Aflac Incorporated reported its first-quarter 2026 earnings, revealing a slight miss on earnings per share (EPS) but a significant beat on revenue. The company’s adjusted EPS was $1.75, falling short of the forecasted $1.80. However, Aflac exceeded revenue expectations with $4.35 billion, surpassing the forecast of $4.18 billion.

In corporate governance developments, Aflac shareholders approved the election of 11 directors to the board and endorsed a non-binding advisory vote on executive compensation at their annual meeting. They also ratified KPMG LLP as Aflac’s independent registered public accounting firm for the year ending December 31, 2026. However, a proposal for an independent board chairman was rejected. Additionally, Aflac has opened a new office in South Portland, Maine, to administer the state’s Paid Family and Medical Leave program, which began issuing benefits recently. This facility will serve over 500,000 eligible workers and participating employers in the area.

The intersection of insider trading activity, financial performance, and corporate governance updates provides a snapshot of the current operational environment for Aflac. The director's sale occurs while the company manages expansion efforts and navigates shareholder expectations following its quarterly results.

Risks

  • Valuation concerns are present, as market analysis indicates the stock appears slightly overvalued relative to its Fair Value.
  • Corporate governance uncertainty is highlighted by the rejection of a proposal for an independent board chairman during the annual meeting.
  • Financial performance volatility is indicated by the discrepancy between revenue beats and earnings per share misses in recent quarterly reporting.

More from Insider Trading

Vicor Executive Offloads Shares Under Pre-Arranged Plan Jun 24, 2026 Aquestive Therapeutics Director Julie Krop Sells $125k in Stock Jun 24, 2026 ACCESS Newswire Executive Brian Balbirnie Executes $11,725 Stock Divestment Jun 24, 2026 Horizon Kinetics Increases Stake in RENN Fund With $2,079 Share Purchase Jun 24, 2026 UroGen Pharma Insider Sale: CMO Schoenberg Offloads $350K in Shares Amid Patent Victory and Clinical Momentum Jun 24, 2026